Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension

NCT01725269 is registered in ClinicalTrials.gov with Aires Pharmaceuticals, Inc. as lead sponsor.

NCT NCT01725269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01725269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Open-Label Study to Evaluate the Intermediate/Long Term Safety and Efficacy of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension
Lead sponsor
Aires Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
March 31, 2013
Completion date
April 30, 2014
Enrollment
17 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension